Image-guided pro-angiogenic therapy in diabetic stroke mouse models using a multi-modal nanoprobe

Theranostics

Volumn 4, Issue 8, 2014, Pages 787-797

  Bai, Ying Ying ^a   Gao, Xihui ^b   Wang, Yuan Cheng ^a   Peng, Xin Gui ^a   Chang, Di ^a   Zheng, Shuyan ^b   Li, Cong ^b   Ju, Shenghong ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Diabetes mellitus; Endothelial progenitor cells; Ischemic stroke; Molecular imaging; Nanoparticle

Indexed keywords

VITRONECTIN RECEPTOR; ANGIOGENIC FACTOR; BETA3 INTEGRIN; CD51 ANTIGEN; NANOPARTICLE;

ACCURACY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CELL THERAPY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL PROGENITOR CELL; FLUORESCENCE IMAGING; HISTOPATHOLOGY; MALE; MICROVASCULATURE; MOUSE; NANOPROBE; NEAR INFRARED SPECTROSCOPY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRO ANGIOGENIC THERAPY; PROTEIN EXPRESSION; PROTEIN TARGETING; THERAPY EFFECT; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CELL DEATH; CHEMISTRY; COMPLICATION; DIABETES COMPLICATIONS; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; DISEASE MODEL; DRUG EFFECTS; ENDOCYTOSIS; ENDOTHELIUM CELL; METABOLISM; PATHOLOGY; PROCEDURES; SPECTROFLUOROMETRY; STROKE; TISSUE DISTRIBUTION; TOXICITY; TUMOR CELL LINE;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BRAIN ISCHEMIA; CELL DEATH; CELL LINE, TUMOR; DIABETES COMPLICATIONS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; ENDOCYTOSIS; ENDOTHELIAL CELLS; INTEGRIN ALPHAV; INTEGRIN BETA3; MAGNETIC RESONANCE IMAGING; MALE; MICE, INBRED C57BL; MICROVESSELS; NANOPARTICLES; NEOVASCULARIZATION, PHYSIOLOGIC; SPECTROMETRY, FLUORESCENCE; STROKE; TISSUE DISTRIBUTION;

EID: 84902532365     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.9525     Document Type: Article

References (41)

1. Navaratna D, Guo SZ, Hayakawa K, et al. Decreased cerebrovascular brain-derived neurotrophic factor-mediated neuroprotection in the diabetic brain. Diabetes. 2011; 60: 1789-96.
2. Kaarisalo MM, Raiha I, Sivenius J, et al. Diabetes worsens the outcome of acute ischemic stroke. Diabetes Res Clin Pract. 2005; 69: 293-8.
3. Li Q, Atochin D, Kashiwagi S, et al. Deficient eNOS phosphorylation is a mechanism for diabetic vascular dysfunction contributing to increased stroke size. Stroke. 2013; 44: 3183-8.
4. Zhu M, Bi X, Jia Q, et al. The possible mechanism for impaired angiogenesis after transient focal ischemia in type 2 diabetic GK rats: different expressions of angiostatin and vascular endothelial growth factor. Biomed Pharmacother. 2010; 64: 208-13.
5. Charriaut-Marlangue C, Bonnin P, Gharib A, et al. Inhaled nitric oxide reduces brain damage by collateral recruitment in a neonatal stroke model. Stroke. 2012; 43: 3078-84.
6. Zechariah A, ElAli A, Doeppner TR, et al. Vascular endothelial growth factor promotes pericyte coverage of brain capillaries, improves cerebral blood flow during subsequent focal cerebral ischemia, and preserves the metabolic penumbra. Stroke. 2013; 44: 1690-7.
7. Fan Y, Shen F, Frenzel T, et al. Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann Neurol. 2010; 67: 488-97.
8. Zhang ZG, Zhang L, Jiang Q, et al. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res. 2002; 90: 284-8.
9. Taguchi A, Soma T, Tanaka H, et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest. 2004; 114: 330-8.
10. Wang XX, Zhang FR, Shang YP, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol. 2007; 49: 1566-71.
11. Lin W, Xiong L, Han J, et al. External counterpulsation augments blood pressure and cerebral flow velocities in ischemic stroke patients with cerebral intracranial large artery occlusive disease. Stroke. 2012; 43: 3007-11.
12. Winter PM, Caruthers SD, Allen JS, et al. Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles. Magn Reson Med. 2010; 64: 369-76.
13. Schmieder AH, Winter PM, Williams TA, et al. Molecular MR imaging of neovascular progression in the Vx2 tumor with alphavbeta3-targeted paramagnetic nanoparticles. Radiology. 2013; 268: 470-80.
14. Yan H, Wang L, Wang J, et al. Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano. 2012; 6: 410-20.
15. Okada Y, Copeland BR, Hamann GF, et al. Integrin alphavbeta3 is expressed in selected microvessels after focal cerebral ischemia. Am J Pathol. 1996; 149:37-44.
16. Li C, Winnard P Jr, and Bhujwalla ZM. Facile synthesis of 1-(acetic acid)-4,7,10-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraaza-cyclododecane:a reactive precursor chelating agent. Tetrahedron Lett. 2009; 50: 2929-31.
17. Watson BD, Dietrich WD, Busto R, et al. Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann Neurol. 1985; 17:497-504.
18. Chen R, Yu H, Jia ZY, et al. Efficient nano iron particle-labeling and noninvasive MR imaging of mouse bone marrow-derived endothelial progenitor cells. Int J Nanomedicine. 2011; 6: 511-9.
19. Klohs J, Grafe M, Graf K, et al. In vivo imaging of the inflammatory receptor CD40 after cerebral ischemia using a fluorescent antibody. Stroke. 2008; 39:2845-52.
20. Cui X, Chopp M, Zacharek A, et al. The Neurorestorative Benefit of GW3965 Treatment of Stroke in Mice. Stroke. 2013; 44: 153-61.
21. Chen J, Sanberg PR, Li Y, et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke. 2001; 32:2682-8.
22. Wang XY, Ju S, Li C, et al. Non-invasive imaging of endothelial progenitor cells in tumor neovascularization using a novel dual-modality paramagnetic/near-infrared fluorescence probe. PLoS One. 2012; 7: e50575.
23. Xiao Y, Hong H, Matson VZ, et al. Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging. Theranostics. 2012; 2: 757-68.
24. Krupinski J, Kaluza J, Kumar P, et al. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke. 1994; 25: 1794-8.
25. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998; 4: 623-6.
26. Pan D, Schmieder AH, Wang K, et al. Anti-Angiogenesis Therapy in the Vx2 Rabbit Cancer Model with a Lipase-cleavable Sn 2 Taxane Phospholipid Prodrug using αvβ3-Targeted Theranostic Nanoparticles. Theranostics. 2014; 4: 565-78.
27. Cai W, Chen K, Li ZB, et al. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med. 2007; 48: 1862-70.
28. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001; 61:1781-5.
29. Zhu L, Guo N, Li Q, et al. Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe. Theranostics. 2012; 2: 746-56.
30. Ji S, Zheng Y, Shao G, et al. Integrin α(v)β3-targeted radiotracer (99m)Tc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β3 RGD2 therapy. Theranostics. 2013; 3: 816-30.
31. Haubner R, Wester HJ, Reuning U, et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999; 40:1061-71.
32. Choi H, Phi JH, Paeng JC, et al. Imaging of integrin α(V)β(3) expression using (68)Ga-RGD positron emission tomography in pediatric cerebral infarct. Mol Imaging. 2013; 12: 213-7.
33. Hua J, Dobrucki LW, Sadeghi MM, et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation. 2005; 111: 3255-60.
34. Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis. 2008; 32: 200-19.
35. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem. 2004; 261: 187-91.
36. Schiekofer S, Galasso G, Sato K, et al. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol. 2005; 25:1603-9.
37. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964-7.
38. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005; 45: 1449-57.
39. Caballero S, Sengupta N, Afzal A, et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes. 2007; 56: 960-7.
40. Chang J, Li Y, Huang Y, et al. Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway. Diabetes. 2010; 59: 2949-59.
41. Yoo H, Kim JW, Shishkov M, et al. Intra-arterial catheter for simultaneous microstructural and molecular imaging in vivo. Nat Med. 2011; 17: 1680-4.